The Effects of Acetyl-L-Carnitine and Myo/Chiro-Inositol in Patients With PCOS
NCT ID: NCT05767515
Last Updated: 2024-09-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
120 participants
INTERVENTIONAL
2023-07-15
2024-03-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PCOS is not a simple pathophysiologic process for which one treatment address all manifestation. Treatment should target specific manifestations and individualized patient goals. First-line agents for ovulation induction and treatment of infertility in patients with PCOS include metformin and clomiphene alone or in combination. It has been approved as category "A "to regulate ovulation and improves pregnancy rates in women with PCOS . Mostly it result in complication like multiple follicle recruitment rate, multiple pregnancy and thinning of endometrial wall leading to early abortion and endometrial cancers. The use of naturally occurring compounds like myoinositol, D-chiro- inositol and L- carnitine which are already part of human body are expected to produce significant results without any side effects . The proposed study will provide an alternative to current treatments available for infertility due to PCOS. The expected project execution time is 2 years. Thus, the present project will discover new insights about treatment of infertility and thus generate new knowledge which will help Academia, scientists and health care professionals. Results of the study will be disseminated on different forums including to policy makers , Pharmaceutical, national and international agencies. The result will be published in journal both national and international with good impact factors. The outcome of the project will be used as publication in high impact international journals, filling of patents and will also be presented in national and international forums.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Adding L-Carnitine to Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovary Syndrome
NCT03630341
L-Carnitine and Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovary Syndrome
NCT03476356
Effects of Metformin Plus Simvastatin on Polycystic Ovarian Syndrome (PCOS): A Prospective, Randomized, Double-Blind, Placebo-Controlled Study
NCT01021579
Evaluation of the Mixture Myoinositol:D-chiro-inositol 3.6:1 in Women With Polycystic Ovary Syndrome
NCT03201601
Ovulation Induction in Clomiphene Citrate Resistant PCO Women
NCT02341703
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Complementary and alternative medicine approach for the treatment of PCOS is becoming popular in recent years. It is claimed that dietary supplements and herbal remedies are safer than conventional drugs.
Acetyl L-Carnitine : Carnitine a quaternary ammonium compound made in the body from lysine and methionine and is available in an active ( L) and an inactive (D ) form. L-carnitine is available in supplemental form and has significant role in enhancing metabolism, producing energy and protecting against oxidative stress. Role of carnitine in treating insulin resistance is being frequently discussed with reference to accrual of acyl-CoA derivatives (8). Hence as suggested if the normal levels of carnitine in the diabetics and obese patients is ensured the insulin insensitivity can be drastically improved. Further the level of L-carnitine in PCOS patients was found to be considerably less. Follicogensis is a highly energy dependent process on mitochondria. In PCOS the functioning of mitochondria is effected due to inflammation and other deregulations because of accumulation of testosterone and insulin in ovary. It help in transport of lipids from cytosol to mitochondria in breakdown of lipids for production of energy (9) Inositol; Inositols present in plants and animal a member of sugar alcohol comprising nine cyclohexane-1, 2, 3, 4, 5, 6-hexol stereoisomers. Being vitamin like it is made in human body as well as synthetically. It is a component of cell membrane and acts as a second messenger, has important role in release of different autacoids, hormones, and neurotransmitters (10).The promising role of two of its isomers namely Myo-inositol (MI) and D-chiro-inositol (DCI) in the treatment of PCOS has been documented. Studies have demonstrated that performance of MI to induce ovulation in patients with infertility due to PCOS can be improved if DCI is combined to it. Best results are achieved when the two isomers are used in 40:1 ratio which is the normal amount in which they exist in the body (11). Both MI and DCI can influence oxidative and non-oxidative metabolism. Apart from being involved in activation of multiple enzymes MI is involved in glucose transport and DCI in insulin production from B- cells and ATP production (12) DCI contributes in mediating insulin activity mainly on non-ovarian tissues, MI displays specific effects on ovary, chiefly by modulating glucose metabolism and FSH-signaling. Moreover, MI may also improve ovarian functions by modulating steroid metabolism through non-insulin-dependent pathways In PCOS patient due IR there is dysregulation in MI/DCI ratio in non- ovarian tissue related to reduced epimarse activity. However ovaries being insulin sensitive have lower level of MI than DCI due to increase epimerase activity (13).
Rationale The incidence of PCOS is increasing throughout the world. It is much higher in Pakistani women (52%) than Caucasian women (20-25%) and is contributing towards both primary (50%) and secondary (25%) infertility (14). Infertilty has its sociocultural connotations resulting in emotional and mental stress. Infertilty due to PCOS should be treated with nutraceuticals for being natural, cost effective, easily available and with minimum side effects. The inositol isomers in its physiological ratio (40:1) and carnitine as an antioxidant has shown significant effects in regularization of metabolic and endocrine parameters of the body Rationale of the present study is that Inositol and Carnitine alone and in combination may be a better alternate for treatment of infertility in patients with PCOS, compared to Metformin. To the best of our knowledge no study till date is documented for synergistic effects of Acetyl-L Carnitine and inositol isomers when used, in physiological balanced ratio, for infertilty Objectives 1. To compare the effects of Inositol isomers and Acetyl-LCarnitine ( alone and in combination) with Metformin on improving ovulation, pregnancy rate, restoring ovarian function, metabolic balance and perceived stress response in patient with PCOS Hypothesis It is hypothesized that Inositol and Acetyl L-Carnitine alone may produce better or at least comparable results to Metformin in improving Pregnancy rate, ovulation, restoring ovarian function, metabolic balance and perceived stress response in infertile patients with PCOS.
It is also hypothesized that the synergistic action of Inositol isomers and Acetyl L-Carnitine in combination may produce better or at least comparable results to Metformin in improving pregnancy rate, ovulation, restoring ovarian function, metabolic balance and perceived stress response in infertile patients with PCOS STUDY DESIGN: This will be a noncommercial randomized double blind clinical trial (RCT) in which subject and treatment provider will blinded to treatment intervention. In this study we will compare the treatment of naturally occurring nutraceuticals with Metformin (control group) which is used as first line drug in treatment of PCOS for infertile women. The nature of study will be explained in both Pashto and Urdu and informed consent will be taken SETTINHS: OPD patients in Gynecology and Obstetrics Department, Pakistan Institute of Medical Sciences, Islamabad (PIMS) and Bacha Khan Medical Complex, Swabi, (BKMC) KP DURATION: The study is expected to be completed in 1.year with duration for 6 months.
SAMPLE SIZE: The study will include 120 patients with PCOS according to our inclusion of the NIH 2012 extension of ESHRE/ASRM 2003 criteria.
.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Metformin Group
Metformin will be used in dose of 500mg BD daily for 30 infertile female PCOS patients
metformin
Treatment of infertile female with PCOS with inositol isomers and Acetyl-L-Carnitine
Inositol isomers Group
Inositols isomers (Myo inositol and D- Chiro Inositol in its physiological ratio) will be used 2000mg BD Daily for 30 infertile female PCOS patients
metformin
Treatment of infertile female with PCOS with inositol isomers and Acetyl-L-Carnitine
Acetyl-L- Carnitine Group
Acetyl-L-Carnitine will be given in dose of 1000mgBD Daily for 30 infertile female PCOS patients
metformin
Treatment of infertile female with PCOS with inositol isomers and Acetyl-L-Carnitine
Combine Group
Inositol isomers and Acetyl-L-Carnitine will be given in dose of 2000mg and 1000mg respectively BD daily for 30 infertile female PCOS patients
metformin
Treatment of infertile female with PCOS with inositol isomers and Acetyl-L-Carnitine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
metformin
Treatment of infertile female with PCOS with inositol isomers and Acetyl-L-Carnitine
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
35 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Cagliari
OTHER
Khyber Medical University Peshawar
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohsin Shah
Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Khyber Medical University
Peshawar, , Pakistan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Rubin KH, Glintborg D, Nybo M, Abrahamsen B, Andersen M. Development and Risk Factors of Type 2 Diabetes in a Nationwide Population of Women With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2017 Oct 1;102(10):3848-3857. doi: 10.1210/jc.2017-01354.
Orio F, Palomba S. Reproductive endocrinology: New guidelines for the diagnosis and treatment of PCOS. Nat Rev Endocrinol. 2014 Mar;10(3):130-2. doi: 10.1038/nrendo.2013.248. Epub 2013 Dec 10.
Akram M, Roohi N. Endocrine correlates of polycystic ovary syndrome in Pakistani women. J Coll Physicians Surg Pak. 2015 Jan;25(1):22-6.
Chauhan B, Kumar G, Kalam N, Ansari SH. Current concepts and prospects of herbal nutraceutical: A review. J Adv Pharm Technol Res. 2013 Jan;4(1):4-8. doi: 10.4103/2231-4040.107494.
An H, He L. Current understanding of metformin effect on the control of hyperglycemia in diabetes. J Endocrinol. 2016 Mar;228(3):R97-106. doi: 10.1530/JOE-15-0447. Epub 2016 Jan 7.
Mansfield R, Galea R, Brincat M, Hole D, Mason H. Metformin has direct effects on human ovarian steroidogenesis. Fertil Steril. 2003 Apr;79(4):956-62. doi: 10.1016/s0015-0282(02)04925-7.
Morley LC, Tang T, Yasmin E, Norman RJ, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2017 Nov 29;11(11):CD003053. doi: 10.1002/14651858.CD003053.pub6.
Tauqir S, Israr M, Rauf B, Malik MO, Habib SH, Shah FA, Usman M, Raza MA, Shah I, Badshah H, Ehtesham E, Shah M. Acetyl-L-Carnitine Ameliorates Metabolic and Endocrine Alterations in Women with PCOS: A Double-Blind Randomized Clinical Trial. Adv Ther. 2021 Jul;38(7):3842-3856. doi: 10.1007/s12325-021-01789-5. Epub 2021 May 28.
Salehpour S, Nazari L, Hoseini S, Moghaddam PB, Gachkar L. Effects of L-carnitine on Polycystic Ovary Syndrome. JBRA Assist Reprod. 2019 Oct 14;23(4):392-395. doi: 10.5935/1518-0557.20190033.
10. Porcaro G, Bizzarri M, Monastra G, et al Strategies for the treatment of polycystic ovary syndrome (PCOS) women: the role of myoinositol (MI) and d-chiro-inositol (DCI) between diet and therapy. Nova science publishers. 2016 1-18
11. Facchinetti F, Dante G, Neri I. The ratio of MI to DCI and its impact in the treatment of polycystic ovary syndrome: experimental and literature evidences. Front Gynecol Endocrinol 2015;3:103-9.
Heimark D, McAllister J, Larner J. Decreased myo-inositol to chiro-inositol (M/C) ratios and increased M/C epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls. Endocr J. 2014;61(2):111-7. doi: 10.1507/endocrj.ej13-0423. Epub 2013 Nov 2.
Bevilacqua A, Bizzarri M. Inositols in Insulin Signaling and Glucose Metabolism. Int J Endocrinol. 2018 Nov 25;2018:1968450. doi: 10.1155/2018/1968450. eCollection 2018.
Gul M, Khan H, Rauf B, Bukhari SMS, Ehtesham E, Malik MO, Shah FA, Alanazi FE, Shah M. Comparative efficacy of combined myo-inositol and D-chiro inositol versus metformin across PCOS Phenotypes: enhancing ovarian function, ovulation, and stress response in a prospective clinical trial. Naunyn Schmiedebergs Arch Pharmacol. 2025 Jul;398(7):8761-8772. doi: 10.1007/s00210-025-03813-9. Epub 2025 Jan 23.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
F.No.SG-21-153/RDC/691
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
NO:KMU/IBMS/2020/45
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.